171 related articles for article (PubMed ID: 36127483)
1. Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.
Li J; Liu M; Zhang X; Ji L; Yang T; Zhao Y; Wang Z; Liang F; Dai L
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4465-4475. PubMed ID: 36127483
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q; Dai L; Wang Y; Liu S; Liang T; Luo R; Wang S; Lou N; Chen H; Zhou Y; Zhong Q; Yang J; Xing P; Hu X; Liu Y; Zhou S; Yao J; Wu D; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2022 Jul; 71(7):1681-1691. PubMed ID: 34817638
[TBL] [Abstract][Full Text] [Related]
3. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
[No Abstract] [Full Text] [Related]
4. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
5. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
6. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma.
Ibrahiem AT; Eladl E; Toraih EA; Fawzy MS; Abdelwahab K; Elnaghi K; Emarah Z; Shaalan AAM; Ehab Z; Soliman NA
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673047
[TBL] [Abstract][Full Text] [Related]
8. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
10. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
11. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
12. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.
Chang CH; Shih AC; Chang YH; Chen HY; Chao YT; Hsu YC
Front Oncol; 2021; 11():759497. PubMed ID: 34868974
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
15. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.
Wu Y; Lin L; Liu X
Dis Markers; 2020; 2020():7291586. PubMed ID: 32587640
[TBL] [Abstract][Full Text] [Related]
16. The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2
Chang LC; Chen TP; Kuo WK; Hua CC
Dis Markers; 2018; 2018():5068701. PubMed ID: 30305853
[TBL] [Abstract][Full Text] [Related]
17. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
20. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
